Brain Injuries, Traumatic Clinical Trial
Official title:
A Multicenter Trial of Autologous Bone Marrow Mononuclear Cells for the Treatment of Adult Severe Traumatic Brain Injury
Verified date | May 2024 |
Source | The University of Texas Health Science Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the effect of intravenous infusion of autologous bone marrow mononuclear cells (BMMNC) on brain structure and neurocognitive/functional outcomes after severe traumatic brain (TBI) injury in adults. The primary objective is to determine if the intravenous infusion of autologous BMMNC after severe TBI results in structural preservation of global gray matter (GM) volume and white matter (WM) volume and integrity; as well as select regions of interest in the corpus callosum. THe secondary objectives are to determine if autologous BMMNC infusion improves functional and neurocognitive deficits in adults after TBI; reduces the neuroinflammatory response to TBI; evaluate spleen size and splenic blood flow over time using ultrasound and corresponding changes in inflammatory cytokines; and infusion related toxicity and long-term follow-up safety evaluations.
Status | Active, not recruiting |
Enrollment | 37 |
Est. completion date | January 2025 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Adults 18 to 55 years of age on the day of injury, 2. Non-penetrating closed head trauma. 3. Glasgow Coma Score between (GCS) between 3 and 8, (best un-medicated post-resuscitation score during screening). 4. Ability to obtain legally authorized representative consent for participation and complete the BMMNC/Sham harvest and cell/placebo infusion within 48 hours of the initial injury. 5. Ability to speak English or Spanish. Exclusion Criteria: 1. Known history of: 1. previous brain injury, 2. intellectual deficiency or psychiatric condition likely to invalidate our ability to assess post-injury changes in cognition or behavior, 3. neurologic impairment and/or deficit, 4. seizure disorder requiring anti-convulsant therapy, 5. recently treated significant infection, 6. renal disease/altered renal function (post-resuscitation serum creatinine > 1.5 mg/dL), 7. chronic hepatic disease or altered liver function (post-resuscitation SGPT > 150 U/L, and/or T. Bilirubin >1.3 mg/dL), 8. cancer, 9. Chemical or ETOH dependency, 10. immunosuppression (admission WBC < 3X103), 11. HIV positive status; 2. Obliteration of perimesencephalic cistern on initial head CT/MRI suggesting prolonged hypoxic ischemic insult; 3. Initial hospital ICP > 40 mm Hg; 4. Hemodynamic instability at the time of screening defined as SBP < 90mmHg, ongoing fluid resuscitation and/or requirement for inotropic support to maintain MAP at or above normals for age - does not include CPP based inotropic support; 5. Uncorrectable coagulopathy at the time of screening; 6. Unstable pelvic fractures that in the P.I.'s opinion would preclude the bone marrow / sham harvest; 7. Pulmonary contusions defined as a chest x-ray with non-anatomic opacification and PaO2:FiO2 ratio < 250 associated with the mechanism of injury; 8. Greater than AAST Grade III solid or hollow visceral injury of the abdomen and/or pelvis diagnosed by CT or other imaging; 9. Spinal cord injury diagnosed by CT or MR imaging or by clinical findings; 10. Persistent hypoxia defined as SaO2 < 94% for > 30 minutes occurring at any time from hospital admission to time of consent; 11. Positive pregnancy test (if applicable); 12. Concurrent participation in an interventional drug/device research study; 13. Unwillingness to return for follow-up visits; 14. Contraindications to MRI. |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | U.S. Army Medical Research and Development Command, United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups. | Subjects will undergo three 3T-MRI evaluations. The first will occur 7 to 10 days after hospitalization, when clinically stable. The following five pulse sequences constitute a complete imaging session: 1) conventional localizer/scout 2) 3D isotropic T1-weighted MPRAGE 3) 3D isotropic T2-weighted TSE 4) 32-direction single-shot spin-echo diffusion sensitized echo-planar (DTI-32dir) 5) 3D-FLAIR.
The 3T-MRI will be repeated at 1 and 6 months post-injury. Composite scores will be calculated for comparison. |
up to 6 months. Post Head Injury | |
Secondary | Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups. | Group differences in functional and neuropsychological outcomes will be assessed. Outcome scores will be correlated with specific macrostructural and microstructural metrics from the MRI. Composite scores will be calculated for comparison. | Changes From Baseline to 6 mo. Post Head Injury | |
Secondary | Compare neuro-inflammatory biomarkers between groups.. | CSF and plasma samples will be analyzed for neuro-inflammatory biomarkers and comparisons made between groups. | Changes From Baseline to 6 mo. Post Head Injury | |
Secondary | Measure the number of participants with infusion related adverse events. | Infusion related adverse events will be determined from analysis of standard of care ICU monitoring data and comparisons made between groups. | up to 6 mo. Post Head Injury | |
Secondary | Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines. | Spleen ultrasound volume will be measured. A comparison of results between groups will help in understanding the contribution of the spleen in the systemic inflammatory responses after acute TBI. | up to 6 mo. Post Head Injury | |
Secondary | Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol). | Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs. | 1 yr. Post Head Injury | |
Secondary | Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures. | Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs. | 1 yr. Post Head Injury | |
Secondary | Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging. | Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs. | 1 yr. Post Head Injury |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04111549 -
GOALS Cognitive Training Delivered to Aging Veterans in Person or Via Telehealth
|
N/A | |
Recruiting |
NCT05097261 -
Ketamine in Acute Brain Injury Patients.
|
Phase 4 | |
Completed |
NCT03504709 -
REsting and Stimulus-based Paradigms to Detect Organized NetworkS and Predict Emergence of Consciousness
|
||
Recruiting |
NCT03899532 -
Remote Ischemic Conditioning in Traumatic Brain Injury
|
N/A | |
Completed |
NCT05057377 -
Estimating Highest Capacity Performance During Evaluation of Walking for Individuals With Traumatic Brain Injury
|
||
Withdrawn |
NCT02776488 -
Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)
|
Phase 2 | |
Completed |
NCT02426749 -
Treatment and Recovery Monitoring of Post TBI Symptoms
|
N/A | |
Completed |
NCT01339702 -
The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines
|
||
Recruiting |
NCT05977270 -
The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury
|
N/A | |
Recruiting |
NCT04666766 -
Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers
|
N/A | |
Active, not recruiting |
NCT04559724 -
Gait Training Through a Novel Over-ground Wearable Robotic System in People With Pyramidal Hemisyndromes
|
N/A | |
Not yet recruiting |
NCT04515420 -
The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury
|
||
Not yet recruiting |
NCT05569993 -
Glutamine and Traumatic Brain Injury
|
Early Phase 1 | |
Recruiting |
NCT04331392 -
Online Memory Intervention for Individuals With Traumatic Brain Injury
|
N/A | |
Completed |
NCT03727737 -
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI
|
N/A | |
Completed |
NCT03153397 -
Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial)
|
N/A | |
Completed |
NCT01336413 -
Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans
|
Phase 2 | |
Completed |
NCT02004080 -
CREACTIVE - Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe
|
||
Completed |
NCT04957563 -
Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia
|
N/A | |
Completed |
NCT05179330 -
Visual Feedback in Lower Limb Rehabilitation
|
N/A |